GLP-1 RECEPTOR AGONISTS AND APPLICATION THEREOF Russian patent published in 2022 - IPC C07D401/14 C07D405/14 C07D413/14 C07D471/14 A61K31/4427 A61K31/497 A61K31/506 A61P3/10 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound by the formula I or a pharmaceutically acceptable salt thereof, exhibiting agonistic activity against the GLP-1 receptor and applicable in treatment of diseases associated therewith. In the formula I, A represents A1 or A2, each R¹ independently represents a halogen or -CN; m equals 0, 1, 2, or 3; X-L represents N-CH₂, CHCH₂, or cyclopropyl; Y represents CH or N; Z^A1 represents CH, CR², or N; Z^A2 represents CH, CR², or N; Z^A3 represents CH, CR², or N; provided that Z^A2 and Z^A3 are simultaneously not N, and additionally provided that one of Z^A2 and Z^A3 represents N when X-L represents N-CH₂; each R² represents F; each R³ independently represents a -C_1-3alkyl; q equals 0, 1 or 2; R⁴ represents a -C_1-3alkyl, -C_0-3alkylene-R⁵ or -C_1-3alkylene-R⁶, wherein said alkyl can be substituted, as permitted by the valency, 0 to 3 substituents independently selected from 0 to 3 F atoms and 0 to 1 substituent selected from -C_0-1alkylene-OR^O; R⁵ represents a 4-6-membered heterocycloalkyl containing 1 to 2 heteroatoms independently selected from N and O, wherein said heterocycloalkyl can be substituted with 0-1 oxo (=O); R⁶ represents a 5-6-membered heteroaryl containing 2 to 3 heteroatoms independently selected from N and O, wherein said heteroaryl can be substituted with 0 to 2 substituents, as permitted by the valency, independently selected from 0-2 -C_1-3alkyls; each R^O independently represents H or a C_1-3alkyl; each of Z¹, Z² and Z³ represents -CR^Z or one of Z¹, Z² and Z³ represents N and the other two represent -CR^Z; and each R^Z independently represents H. The invention also relates to specific compounds, a pharmaceutical composition, and a method for treating a cardiometabolic disease and diseases associated therewith.

EFFECT: creation of a compound for treating diseases associated with the GLP-1 receptor.

20 cl, 11 tbl, 80 ex